Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Virbac    VIRP   FR0000031577

VIRBAC (VIRP)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Latest news on VIRBAC
04/12VIRBAC : 2018 first quarter consolidated sales
PU
04/12VIRBAC : 2018 first quarter revenue rose by +3.3% at comparable exchange rates
GL
04/12VIRBAC : 2018 first quarter revenue rose by +3.3% at comparable exchange rates
AQ
04/12VIRBAC : 1st quarter earnings
CO
03/31VIRBAC : Monthly statement on outstanding equity shares and voting rights
CO
03/14VIRBAC : operating profit from ordinary activities 2017 comparable to 2016
GL
03/09VIRBAC SA : annual earnings release
02/23VIRBAC : strengthens its R&D in Asia
PU
01/16VIRBAC : annual sales comparable to 2016 at constant exchange rates after strong..
GL
01/11VIRBAC SA : annual sales release
01/08VIRBAC : Happy new year!
PU
2017VIRBAC : Sébastien Huron officially takes office as chairman of the Virbac group..
PU
2017VIRBAC : StMichel-Virbac wins the 2017 Transat Jacques Vabre sailing race from F..
PU
2017CHINA : Virbac acclaimed by the largest pet owners community
PU
2017AQUACULTURE : Virbac postpones its option to buy Centrovet for three years
PU
2017VIRBAC : Aquaculture: Virbac postpones its option to buy Centrovet for three yea..
GL
2017VIRBAC : Availability of the quarterly financial information as of September 30,..
GL
2017VIRBAC : Availability of the quarterly financial information as of September 30,..
AQ
2017VIRBAC : does not extend its sailing sponsorship
PU
2017VIRBAC : 2017 third quarter consolidated sales
PU
2017VIRBAC : quarterly sales affected by distributor destocking in the United State..
GL
2017VIRBAC SA : quaterly sales release
2017VIRBAC GROUP : Solène Madelpuech joins the supervisory board
PU
2017European shares end at five-week high as relief bounce continues
RE
2017VIRBAC : 2017 half year results
PU
2017VIRBAC : Availability of the first half-yearly financial report as of June 30, 2..
GL
2017VIRBAC : slight increase in first half results
GL
2017VIRBAC : Availability of the first half-yearly financial report as of June 30, 2..
AQ
2017VIRBAC SA : half-yearly earnings release
2017VIRBAC : 2017 second quarter consolidated sales
PU
2017VIRBAC : second quarter sales growth largely offsets the decline in the first qu..
GL
2017VIRBAC SA : half-yearly sales release
2017VIRBAC : Sébastien Huron will become the new chairman of the executive board as ..
GL
2017VIRBAC : Sébastien Huron will become the new chairman of the executive board as ..
AQ
2017VIRBAC : signs a research agreement with Bio-Gene
PU
2017VIRBAC : United States selects KC Animal Health Corridor for North American dist..
PU
2017VIRBAC : Availability of quarterly Financial information as of March 31st 2017
GL
2017VIRBAC : Availability of annual report 2016
GL
2017VIRBAC : Apr 12 - 2017 first quarter consolidated sales
PU
2017VIRBAC : first quarter 2017 sales down, strongly impacted by stock effects in th..
GL
2017VIRBAC SA : quaterly sales release
2017VIRBAC : strong rebound in profitability in 2016
GL
2017VIRBAC SA : annual earnings release
2017VIRBAC : annual sales growth of 4.5%, at constant exchange rates
GL
2017VIRBAC SA : annual sales release
2016VIRBAC : Oct 13 - 2016 third quarter consolidated sales
PU
2016VIRBAC : sales grow by 3.2% at the end of September at constant rates
GL
2016VIRBAC SA : quaterly sales release
2016VIRBAC : Sep 19 - 2016 half year results
PU
2016VIRBAC : growth of half-year results
GL
2016VIRBAC : Availability of the half-yearly financial report as of June 30, 2016
GL
2016VIRBAC SA : half-yearly earnings release
2016VIRBAC : sales grow by 3.6% at constant exchange rates in the first half
GL
2016VIRBAC SA : half-yearly sales release
2016VIRBAC : Declaration of the number of shares and voting rights as of June 2016, ..
GL
2016VIRBAC : Declaration of the number of shares and voting rights as of May 2016, 3..
GL
2016VIRBAC : Availability of the quarterly Financial information as of March 31,2016
GL
2016VIRBAC : Declaration of the number of shares and voting rights as of April 2016,..
GL
2016VIRBAC : Availability of Annual Financial Report 2015
GL
2016VIRBAC : sales in the first quarter 2016: return to organic growth
GL
2016VIRBAC : Declaration of the number of shares and voting rights as of March 2016,..
GL
2016VIRBAC : 2015 annual results heavily impacted by the United States
GL
2016VIRBAC : Declaration of the number of shares and voting rights as of February 20..
GL
2016VIRBAC : Declaration of the number of shares and voting rights as of January, 31..
GL
2016VIRBAC : annual sales growth of 10.2%, driven by exchange rates and acquisitions
GL
2016VIRBAC : Declaration of the number of shares and voting rights as of December 20..
GL
2015VIRBAC : Declaration of the number of shares and voting rights as of November 20..
GL
2015VIRBAC : Availaibility of quarterly Financial information as of September 30, 20..
GL
2015VIRBAC : Declaration of the number of shares and voting rights, October 2015
GL
2015VIRBAC : sales grow by 5.5% in the third quarter
GL
2015VIRBAC : Declaration of the number of shares and voting rights as of september 2..
GL
2015VIRBAC : 2015 half year results
PU
2015VIRBAC : Availability of half yearly financial report - June 2015
GL
2015VIRBAC : half-year results heavily impacted by the United States
GL
2015VIRBAC : Declaration of the number of shares and voting rights as of August 2015..
GL
1  2  3Next
Financials (€)
Sales 2018 902 M
EBIT 2018 75,4 M
Net income 2018 36,4 M
Debt 2018 550 M
Yield 2018 0,89%
P/E ratio 2018 29,44
P/E ratio 2019 23,09
EV / Sales 2018 1,83x
EV / Sales 2019 1,73x
Capitalization 1 101 M
Chart VIRBAC
Duration : Period :
Virbac Technical Analysis Chart | VIRP | FR0000031577 | 4-Traders
Technical analysis trends VIRBAC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 123 €
Spread / Average Target -3,7%
EPS Revisions
Managers
NameTitle
Sébastien Huron Chairman-Executive Board
Marie-Hélène Dick-Madelpuech Chairman-Supervisory Board
Habib Ramdani Chief Financial Officer
Philippe Gaston H. Capron Member-Supervisory Board
Pierre Madelpuech Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
VIRBAC5.43%1 359
ZOETIS18.92%41 728
DECHRA PHARMACEUTICALS31.49%3 993
JINYU BIO-TECHNOLOGY CO LTD49.34%3 526
PHIBRO ANIMAL HEALTH CORP31.19%1 766
PULIKE BIOLOGICAL ENGINEERING INC-10.23%1 033